Deciphera Pharmaceuticals (NASDAQ:DCPH) Upgraded at BidaskClub

BidaskClub upgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a buy rating to a strong-buy rating in a report issued on Wednesday morning, BidAskClub reports.

Several other equities analysts have also recently commented on the stock. ValuEngine cut shares of Deciphera Pharmaceuticals from a hold rating to a sell rating in a research report on Saturday, October 19th. Zacks Investment Research cut Deciphera Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, November 7th. Leerink Swann raised Deciphera Pharmaceuticals from an underperform rating to a market perform rating in a report on Tuesday, October 29th. HC Wainwright began coverage on Deciphera Pharmaceuticals in a report on Thursday, October 3rd. They set a buy rating and a $60.00 target price on the stock. Finally, JMP Securities lifted their target price on Deciphera Pharmaceuticals from $45.00 to $54.00 and gave the stock a market outperform rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Deciphera Pharmaceuticals presently has a consensus rating of Buy and an average price target of $49.31.

DCPH traded up $1.42 during trading on Wednesday, hitting $52.80. The company had a trading volume of 249,047 shares, compared to its average volume of 412,017. Deciphera Pharmaceuticals has a 1-year low of $19.69 and a 1-year high of $52.81. The company has a market cap of $2.70 billion, a PE ratio of -18.72 and a beta of 1.94. The business has a 50-day moving average of $44.62 and a 200-day moving average of $32.30.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings data on Monday, November 4th. The company reported ($1.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by ($0.09). Sell-side analysts predict that Deciphera Pharmaceuticals will post -4.25 earnings per share for the current year.

In other Deciphera Pharmaceuticals news, insider Daniel Lee Flynn sold 152,927 shares of Deciphera Pharmaceuticals stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $48.91, for a total value of $7,479,659.57. Also, CFO Thomas Patrick Kelly sold 11,250 shares of Deciphera Pharmaceuticals stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $34.97, for a total value of $393,412.50. In the last quarter, insiders have sold 263,281 shares of company stock worth $12,181,518. 7.02% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Redmile Group LLC boosted its position in Deciphera Pharmaceuticals by 115.0% during the 3rd quarter. Redmile Group LLC now owns 4,780,898 shares of the company’s stock valued at $162,264,000 after purchasing an additional 2,557,522 shares during the period. Pictet Asset Management Ltd. acquired a new position in shares of Deciphera Pharmaceuticals during the third quarter valued at $15,608,000. BlackRock Inc. boosted its holdings in shares of Deciphera Pharmaceuticals by 25.6% during the second quarter. BlackRock Inc. now owns 1,531,844 shares of the company’s stock valued at $34,543,000 after acquiring an additional 311,870 shares during the period. Point72 Asset Management L.P. bought a new position in shares of Deciphera Pharmaceuticals during the second quarter worth about $4,606,000. Finally, State Street Corp grew its position in shares of Deciphera Pharmaceuticals by 19.7% during the third quarter. State Street Corp now owns 754,236 shares of the company’s stock worth $25,599,000 after acquiring an additional 124,005 shares during the last quarter. 69.45% of the stock is currently owned by institutional investors and hedge funds.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Featured Story: What is intrinsic value?

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.